Art

J-GLOBAL ID：201802243843251621   Reference number：18A0000653

Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis

日本における膵癌に対するエルロチニブ+ゲムシタビンの市販後調査:POLARIS最終解析

Author (10)： FURUSE Junji (Kyorin Univ. School of Medicine, Tokyo) ,  FURUSE Junji (Independent Advisory Board for Erlotinib, Tokyo) ,  GEMMA Akihiko (Independent Advisory Board for Erlotinib, Tokyo) ,  GEMMA Akihiko (Nippon Medical School Graduate School of Medicine, Tokyo) ,  ICHIKAWA Wataru (Independent Advisory Board for Erlotinib, Tokyo) ,  ICHIKAWA Wataru (Showa Univ. Fujigaoka Hospital, Tokyo) ,  OKUSAKA Takuji (Independent Advisory Board for Erlotinib, Tokyo) ,  OKUSAKA Takuji (National Cancer Center Hospital, Tokyo) ,  SEKI Akihiro (Chugai Pharmaceuticals Ltd, Tokyo, JPN) ,  ISHII Tadashi (Chugai Pharmaceuticals Ltd, Tokyo, JPN)
Material： Japanese Journal of Clinical Oncology (Web)  (JJCO (Web))
Volume： 47  Issue： 9  Page： 832-839 (WEB ONLY)  Publication year： Sep. 2017 
JST Material Number： U1085A  ISSN： 1465-3621  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： *pancreatic tumor ,...
Semi thesaurus term： *Pancreatic adenocarcinoma metastatic ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A0000653&from=J-GLOBAL&jstjournalNo=U1085A") }}

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Tumors(=neoplasms)of digestive system  (GH04000D)

Substance index (2)： Erlotinib ,  Gemcitabine

Reference (30)：

• World Health Organization, GLOBOCAN 2012 (http: //globocan.iarc.fr/). Last accessed 15 February 2017.
• Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15: 2403-13.
• Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-5.
• Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer 2002;94:902-10.
• Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.

Terms in the title (6)： 日本 ,  膵癌 ,  エルロチニブ ,  ゲムシタビン ,  市販後調査 ,  解析